Researchers presented detailed analyses of a gene therapy death in a brain disease trial, moving the field from raw shock toward a more testable risk framework. The work stops short of assigning a definitive cause of death, but outlines experiments meant to identify and screen future therapies for similar hazards. Capsida Biotherapeutics’ Nicholas Flytzanis said the goal is to build a framework for “testing this” and mitigating a specific novel risk, rather than treating the event as an unresolvable anomaly. The disclosure emphasizes structured follow-up research after serious adverse events that raised fear and uncertainty across neurogene therapy programs. For developers, the update underscores that regulators and clinicians are likely to scrutinize mechanistic risk mitigation plans—not just safety signals—after rare but severe outcomes.